Our product
is a lateral flow point-of-care test able to detect a novel biomarker, produced by the host immune system in response to bacterial infection in one drop of blood within 20 minutes.
Delta's proprietary biomarker is exclusively licensed from
Heidelberg University.
Superior biomarker performance in the early diagnosis of Sepsis
Delta detects and excludes sepsis with an outstanding accuracy already when the first unspecific symptoms occur
.png)
Superior Biomarker quality
Our patented technology
Activation marker of the immune system for the early diagnosis of sepsis
-
Upregulated in immune cells upon infection
-
Liberated into the blood
-
Highly elevated concentration in blood of patients with sepsis
-
Lower concentration in patients with mutiple trauma and surgery (“sterile inflammation“), autoimmune disease and viral infection
Publications
Host-Derived Delta-Like Canonical Notch Ligand 1 as a Novel Diagnostic Biomarker for Bacterial Sepsis—Results From a Combinational Secondary Analysis
Hildebrand et al., 2019, Front. Cell. Infect. Microbiol.
Delta-Like Canonical Notch Ligand 1 in Patients Following Liver Transplantation—A Secondary
Analysis of a Prospective Cohort Study
Decker et al., 2020, Diagnostics
The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes
Hildebrand et al., 2018, Front Cell Infect Microbiol.
Biomarkers of sepsis: time for a reappraisal
Pierrakos et al., 2020, Critical care